• Image



  1. Albert SF and Weis ZH. Management of onychomycosis with topicals. Clin Podiatr Med Surg 2004;21(4):605-15.
  2. AT Still University. The Fungi. http://www.atsu.edu/faculty/chamberlain/Website/Lects/Fungi.htm. Accessed 28/05/10.
  3. Baran R et al. A new classification of onychomycosis. Br J Dermatol 1998;139(4):567-71.
  4. Baran et al eds. Baran and Dawber’s Diseases of the Nails and Their Management. Oxford, UK: Blackwell Science Ltd; 2001
  5. Baran R and Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005;19(1):21-9.
  6. Baran R. Mycologial Examination. In: Baran R, Hay RJ, Haneke E, Tosti A eds. Onychomycosis: The Current Approach to Diagnosis and Therapy. 2nd Edition. Boca Raton, FL: Taylor & Francis. 2006; 30-34
  7. Bonnetblanc JM. Onychomycoses: recommandations pour la pratique clinique. Ann Dermatol Venereol. 2007 May;134(3):5S7-16.
  8. de Berker D. Clinical practice. Fungal nail disease. N Engl J Med 2009;360(20):2108-16.
  9. Burzykowski T et al. High prevalence of foot diseases in Europe: results of the Achilles Project.Mycoses 2003;46(11-12):496-505.
  10. Effendy I, Lecha M, Feuilhade de Chauvin M, Di Chiacchio N, Baran R; European Onychomycosis Observatory. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol 2005;19 Suppl 1:8-12.
  11. Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol. 1997 Oct;36(10):754-6.
  12. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998;11(3):415-29.
  13. Elkeeb R et al. Transungual drug delivery: current status. Int J Pharm 2010;384(1-2):1-8.
  14. Gupta AK and Tu LQ. Onychomycosis therapies: strategies to improve efficacy. Dermatol Clin 2006;24(3):381-6.
  15. Hui X et al. Ciclopirox delivery into the human nail plate. J Pharm Sci 2004;93(10):2545-8.
  16. Jayatilake JA, et al. Candidal onychomycosis: a mini-review. Mycopathologia 2009;168(4):165-73.
  17. Katsambas A et al.The effects of foot disease on quality of life: results of the Achilles Project. J Eur Acad Dermatol Venereol 2005;19(2):191-5.
  18. olde Hartman TC and van Rijswijk E. Fungal nail infection. BMJ 2008;337:a429.
  19. Roberts DT et al; British Association of Dermatologists. Guidelines for treatment of onychomycosis. Br J Dermatol 2003;148(3):402-10.
  20. Sáez de Ocariz MM et al. Frequency of toenail onychomycosis in patients with cutaneous manifestations of chronic venous insufficiency. Int J Dermatol 2001;40(1):18-25.
  21. Scher RK et al. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 2007;56(6):939-44.
  22. Seebacher C, et al. Onychomycosis. J Dtsch Dermatol Ges 2007;5(1):61-6.
  23. Société Française de Dermatologie. Modalités de diagnostic et prise en charge des onychomycoses. Ann Dermatol Venereol 2007;134:5S7-16.
  24. Szepietowski JC, et al. Evaluation of quality of life in patients with toenail onychomycosis by Polish version of an international onychomycosis-specific questionnaire. J Eur Acad Dermatol Venereol 2007;21(4):491-6.
  25. Tosti A et al. Patients at risk of onychomycosis--risk factor identification and active prevention. J Eur Acad Dermatol Venereol 2005;19 Suppl 1:13-6.
  26. Trosyl nail solution Summary of Product Characteristics (SmPC). Pfizer.
  27. Université de Lyon. Cours de Mycologie. http://ispb.univ-lyon1.fr/mycologie/Site_labo_myco/Enseignement/4/UV04.htm. Accessed 28/05/10.
  28. Warshaw EM et al. NailQoL: a quality-of-life instrument for onychomycosis. Int J Dermatol 2007;46(12):1279-86.

Follow us Follow us on twitter Follow us on Linkedin

Corporate responsibility

Growing a responsible dermatological community

Discover some of the positive initiatives we are involved in across the world



We are committed

See all videos